Semin Liver Dis 2020; 40(01): 001-010
DOI: 10.1055/s-0039-1697616
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Peculiarities of Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

Omar El-Sherif
1   Liver Unit, Queen Elizabeth University Hospital Birmingham, Birmingham, United Kingdom
,
M.J. Armstrong
1   Liver Unit, Queen Elizabeth University Hospital Birmingham, Birmingham, United Kingdom
2   NIHR Birmingham Biomedical Research Centre, Centre for Liver Research, University of Birmingham, Birmingham, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
19 September 2019 (online)

Abstract

The prevalence of cirrhosis due to nonalcoholic steatohepatitis (NASH) has increased 2.5-fold in the United States in the last decade. These patients pose new challenges to hepatologists given their older age and higher frequency of coexisting metabolic diseases such as obesity and diabetes compared with other etiologies of liver disease. Patients with NASH cirrhosis are at higher risk for renal and cardiovascular disease, and the presence of these extrahepatic comorbidities has a significant impact on outcomes and survival. This review outlines how NASH cirrhosis differs from other etiologies of cirrhosis including natural history, noninvasive assessment, and the challenges in the management of the complications of cirrhosis including hepatic encephalopathy and hepatocellular carcinoma. Nutritional assessment and the impact of sarcopenic obesity and frailty in this population, and strategies to address the latter, are discussed. This review also addresses liver transplantation in patients with NASH cirrhosis in relation to assessment and posttransplant care.

Authors' Contributions

O.E.S. and M.J.A. performed the literature search. O.E.S. wrote the first draft. M.J.A. edited the draft and approved the final manuscript.


 
  • References

  • 1 Kabbany MN, Conjeevaram Selvakumar PK, Watt K. , et al. Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of National Health and Nutrition Examination Survey data. Am J Gastroenterol 2017; 112 (04) 581-587
  • 2 Agopian VG, Kaldas FM, Hong JC. , et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg 2012; 256 (04) 624-633
  • 3 Haldar D, Kern B, Hodson J. , et al; European Liver and Intestine Transplant Association (ELITA). Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study. J Hepatol 2019; 71 (02) 313-322
  • 4 Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55 (07) 434-438
  • 5 Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13 (04) 643-54.e1 , 9, quiz e39–e40
  • 6 Hagström H, Nasr P, Ekstedt M. , et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 2017; 67 (06) 1265-1273
  • 7 Bosch J, Harrison SA, Abdelmalek MF. , et al. Hepatic venous pressure gradient (HVPG) predicts clinic disease progression in patients with compensated cirrhosis due to NASH. Hepatology 2017; 66: 244A
  • 8 Bertolotti M, Lonardo A, Mussi C. , et al. Nonalcoholic fatty liver disease and aging: epidemiology to management. World J Gastroenterol 2014; 20 (39) 14185-14204
  • 9 Sanyal AJ, Banas C, Sargeant C. , et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43 (04) 682-689
  • 10 Haflidadottir S, Jonasson JG, Norland H. , et al. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol 2014; 14: 166
  • 11 O'Leary JG, Landaverde C, Jennings L, Goldstein RM, Davis GL. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol 2011; 9 (08) 700-704.e1
  • 12 Moriya A, Iwasaki Y, Ohguchi S. , et al. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 33 (03) 378-388
  • 13 Ekstedt M, Franzén LE, Holmqvist M. , et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol 2009; 44 (03) 366-374
  • 14 Ratziu V. A critical review of endpoints for non-cirrhotic NASH therapeutic trials. J Hepatol 2018; 68 (02) 353-361
  • 15 Gilead Sciences Press Release. Available at: https://www.gilead.com/news-and-press/press-room/press-releases/2019/2/gilead-announces-topline-data-from-phase-3-stellar4-study-of-selonsertib-in-compensated-cirrhosis-f4-due-to-nonalcoholic-steatohepatitis-nash . Accessed February 11, 2019
  • 16 Garcia-Tsao G, Bosch J, Kayali Z. , et al. Double-blind, placebo-controlled, randomised trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension. EASL International Liver Congress, Vienna, April 2019
  • 17 Afdhal N, Everson GT, Calleja JL. , et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat 2017; 24 (10) 823-831
  • 18 Harrison SA, Abdelmalek MF, Caldwell S. , et al; GS-US-321-0105 and GS-US-321-0106 Investigators. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by non-alcoholic steatohepatitis. Gastroenterology 2018; 155 (04) 1140-1153
  • 19 Rockey DC. Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. Gastroenterology 2008; 134 (01) 8-14
  • 20 Castéra L, Foucher J, Bernard PH. , et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51 (03) 828-835
  • 21 Wong VW, Vergniol J, Wong GL. , et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012; 107 (12) 1862-1871
  • 22 Singh S, Muir AJ, Dieterich DT, Falck-Ytter YT. American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases. Gastroenterology 2017; 152 (06) 1544-1577
  • 23 Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology 2017; 66 (05) 1486-1501
  • 24 Castera L, Friedrich-Rust M, Loomba R. Non-invasive assessment of liver disease in patients with non-alcoholic fatty liver disease. Gastroenterology 2019; 156 (05) 1264-1281.e4
  • 25 de Franchis R, Baveno VI. ; Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63 (03) 743-752
  • 26 Petta S, Sebastiani G, Bugianesi E. , et al. Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. J Hepatol 2018; 69 (04) 878-885
  • 27 Shearer J, Chizhande D, Jones R, Rowe IA. Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease. J Hepatol 2018; 69 (05) 1202-1203
  • 28 Cabassa P, Ravanelli M, Rossini A, Contessi G, Almajdalawi R, Maroldi R. Acoustic radiation force impulse quantification of spleen elasticity for assessing liver fibrosis. Abdom Imaging 2015; 40 (04) 738-744
  • 29 Wong GL, Liang LY, Kwok R. , et al. Low risk of variceal bleeding in patients with cirrhosis after variceal screening stratified by liver/spleen stiffness. Hepatology 2019; DOI: 10.1002/hep.30522.
  • 30 Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant 2014; 14 (08) 1870-1879
  • 31 Lai JC, Dodge JL, Sen S, Covinsky K, Feng S. Functional decline in patients with cirrhosis awaiting liver transplantation: results from the functional assessment in liver transplantation (FrAILT) study. Hepatology 2016; 63 (02) 574-580
  • 32 Merli M, Lattanzi B, Aprile F. Sarcopenic obesity in fatty liver. Curr Opin Clin Nutr Metab Care 2019; 22 (03) 185-190
  • 33 Berzigotti A, Garcia-Tsao G, Bosch J. , et al; Portal Hypertension Collaborative Group. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 2011; 54 (02) 555-561
  • 34 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol 2019; 70 (01) 172-193
  • 35 Saab S, Lalezari D, Pruthi P, Alper T, Tong MJ. The impact of obesity on patient survival in liver transplant recipients: a meta-analysis. Liver Int 2015; 35 (01) 164-170
  • 36 Hayashi F, Momoki C, Yuikawa M. , et al. Nutritional status in relation to lifestyle in patients with compensated viral cirrhosis. World J Gastroenterol 2012; 18 (40) 5759-5770
  • 37 Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L. , et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149 (02) 367-78.e5 , quiz e14–e15
  • 38 Pi-Sunyer X, Blackburn G, Brancati FL. , et al; Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007; 30 (06) 1374-1383
  • 39 Berzigotti A, Albillos A, Villanueva C. , et al; Ciberehd SportDiet Collaborative Group. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study. Hepatology 2017; 65 (04) 1293-1305
  • 40 Kruger C, McNeely ML, Bailey RJ. , et al. Home exercise training improves exercise capacity in cirrhosis patients: role of exercise adherence. Sci Rep 2018; 8 (01) 99
  • 41 Williams FR, Vallance A, Faulkner T. , et al. Home-based exercise in patients awaiting liver transplantation: a feasibility study. Liver Transpl 2019; 25 (07) 995-1006
  • 42 Dyson J, Jaques B, Chattopadyhay D. , et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014; 60 (01) 110-117
  • 43 El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126 (02) 460-468
  • 44 Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51 (06) 1972-1978
  • 45 Sanyal A, Poklepovic A, Moyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010; 26 (09) 2183-2191
  • 46 Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?. Arch Pathol Lab Med 2008; 132 (11) 1761-1766
  • 47 Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci 2016; 17 (05) 774
  • 48 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. Management of hepatocellular carcinoma. J Hepatol 2018; 69 (01) 182-236
  • 49 Heimbach JK, Kulik LM, Finn RS. , et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67 (01) 358-380
  • 50 Wong LL, Reyes RJ, Kwee SA, Hernandez BY, Kalathil SC, Tsai NC. Pitfalls in surveillance for hepatocellular carcinoma: how successful is it in the real world?. Clin Mol Hepatol 2017; 23 (03) 239-248
  • 51 Stine JG, Shah NL, Argo CK, Pelletier SJ, Caldwell SH, Northup PG. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. Liver Transpl 2015; 21 (08) 1016-1021
  • 52 Weinberg EM, Palecki J, Reddy KR. Direct-acting oral anticoagulants (DOACs) in cirrhosis and cirrhosis-associated portal vein thrombosis. Semin Liver Dis 2019; 39 (02) 195-208
  • 53 De Gottardi A, Thévenot T, Spahr L. , et al. Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol 2009; 7 (08) 906-909
  • 54 Sarma P, Muktesh G, Dhaka N. , et al. Terlipressin-induced peripheral ischaemic gangrene in a diabetic patient. J Pharmacol Pharmacother 2017; 8 (03) 148-150
  • 55 Elzouki AN, El-Menyar A, Ahmed E, Elbadri ME, Imam YZ, Gurbanna BA. Terlipressin-induced severe left and right ventricular dysfunction in patient presented with upper gastrointestinal bleeding: case report and literature review. Am J Emerg Med 2010; 28 (04) 540.e1-540.e6
  • 56 Sanyal AJ, Boyer T, Garcia-Tsao G. , et al; Terlipressin Study Group. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134 (05) 1360-1368
  • 57 Martín-Llahí M, Pépin MN, Guevara M. , et al; TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134 (05) 1352-1359
  • 58 Cavallin M, Piano S, Romano A. , et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology 2016; 63 (03) 983-992
  • 59 Chapman B, Gow P, Sinclair M. , et al. Continuous terlipressin infusion is associated with improved diet intake and muscle strength in patients awaiting liver transplant. J Hep Reports 2019; 1 (02) 107-113
  • 60 Dasani BM, Sigal SH, Lieber CS. Analysis of risk factors for chronic hepatic encephalopathy: the role of Helicobacter pylori infection. Am J Gastroenterol 1998; 93 (05) 726-731
  • 61 Somberg KA, Riegler JL, LaBerge JM. , et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. Am J Gastroenterol 1995; 90 (04) 549-555
  • 62 Dhaliwal A, Armstrong MJ, Tripathi D. Patient selection for transjugular intrahepatic portosystemic shunt (TIPSS) insertion in variceal bleeding and refractory ascites. Curr Hepatol Rep 2017; 16: 241
  • 63 Ferreira LG, Anastácio LR, Lima AS, Touslon Davisson Correia MI. Predictors of mortality in patients on the waiting list for liver transplantation. Nutr Hosp 2013; 28 (03) 914-919
  • 64 Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42 (01) 44-52
  • 65 Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004; 40 (04) 578-584
  • 66 Aron-Wisnewsky J, Minville C, Tordjman J. , et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol 2012; 56 (01) 225-233
  • 67 Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34 (03) 274-285
  • 68 Loomba R, Abraham M, Unalp A. , et al; Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56 (03) 943-951
  • 69 European Association for the Study of the Liver (EASL). European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402
  • 70 Addepally NS, George N, Martinez-Macias R, Garcia-Saenz-de-Sicilia M, Kim WR, Duarte-Rojo A. Hemoglobin A1c has suboptimal performance to diagnose and monitor diabetes mellitus in patients with cirrhosis. Dig Dis Sci 2018; 63 (12) 3498-3508
  • 71 Lahousen T, Hegenbarth K, Ille R. , et al. Determination of glycated hemoglobin in patients with advanced liver disease. World J Gastroenterol 2004; 10 (15) 2284-2286
  • 72 Musso G, Tabibian JH, Charlton M. Chronic kidney disease (CKD) and NAFLD: time for awareness and screening. J Hepatol 2015; 62 (04) 983-984
  • 73 Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 2016; 65 (03) 589-600
  • 74 Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?. J Hepatol 2018; 68 (02) 335-352
  • 75 Hicks S, Mara K, Larson JL. , et al. The incidence of extrahepatic malignancies in non-alcoholic fatty liver disease (NAFLD). AASLD Liver Meeting 2018 , San Francisco, Abstract 0031
  • 76 Ahn JS, Sinn DH, Min YW. , et al. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Ther 2017; 45 (02) 345-353
  • 77 Danford CJ, Iriana S, Shen C, Curry MP, Lai M. Evidence of bias during liver transplant evaluation of non-alcoholic steatohepatitis cirrhosis patients. Liver Int 2019; 39 (06) 1165-1173
  • 78 Thuluvath PJ, Hanish S, Savva Y. Waiting list mortality and transplant rates for NASH cirrhosis when compared with cryptogenic, alcoholic, or AIH cirrhosis. Transplantation 2019; 103 (01) 113-121
  • 79 Tsochatzis E, Coilly A, Nadalin S. , et al. International Liver Transplantation consensus statement on end-stage liver disease due to nonalcoholic steatohepatitis and liver transplantation. Transplantation 2019; 103 (01) 45-56
  • 80 Maddur H, Bourdillon PD, Liangpunsakul S. , et al. Role of cardiac catheterization and percutaneous coronary intervention in the preoperative assessment and management of patients before orthotopic liver transplantation. Liver Transpl 2014; 20 (06) 664-672
  • 81 Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35 (01) 105-109
  • 82 Schlansky B, Naugler WE, Orloff SL, Enestvedt CK. Higher mortality and survival benefit in obese patients awaiting transplantation. Transplantation 2016; 100 (12) 2648-2655
  • 83 Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141 (04) 1249-1253
  • 84 Angulo P, Kleiner DE, Dam-Larsen S. , et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with non-alcoholic fatty liver disease. Gastroenterology 2015; 149 (02) 389-97.e10
  • 85 Younossi ZM, Stepanova M, Rafiq N. , et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011; 53 (06) 1874-1882
  • 86 Sebastiani G, Alshaalan R, Wong P. , et al. Prognostic value of non-invasive fibrosis and steatosis tools, hepatic venous pressure gradient (HVPG) and histology in non-alcoholic steatohepatitis. PLoS One 2015; 10 (06) e0128774